Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
OPKO Health (OPK) will participate in the Wells Fargo 21st Annual Healthcare Conference at Encore Boston Harbor. President and Vice Chairman Elias A. Zerhouni, M.D., and Senior Vice President and Chief Financial Officer Adam Logal will join a fireside chat on Thursday, September 10, 2026, at 9:30 a.m. ET. A live webcast and replay of the session will be available through the OPKO investor relations website.
OPKO Health (NASDAQ: OPK) expanded its financing relationship with HealthCare Royalty (a business of KKR, HCRx) by issuing an additional $125 million of senior secured notes, backed by OPKO’s royalty interests from its mazdutide license with Eli Lilly. The notes mature in 2044, aligned with OPKO’s existing HCRx notes.
According to OPKO, the structure delivers additional non-dilutive capital while capping total payments at 1.5x the funded amount, after which OPKO retains future royalty economics. Mazdutide is commercialized in China by Innovent Biologics, and OPKO began recording related royalty revenue in 2025.
Cocrystal Pharma (Nasdaq: COCP) entered into a $5 million private placement with longtime investor OPKO Health (Nasdaq: OPK). Cocrystal sold 5,474,053 common shares to OPKO at $0.9134 per share, equal to the Nasdaq Consolidated Bid Price on the closing day, with no warrants or other derivatives issued.
According to Cocrystal, the proceeds support advancement of its lead norovirus candidate CDI-988, with topline Phase 1b data expected by the end of the fourth quarter of 2026. Both companies highlighted OPKO’s longstanding support and confidence in Cocrystal’s antiviral pipeline.
OPKO Health (NASDAQ: OPK) reported second quarter 2026 revenues of $163.5 million, up from $156.8 million a year earlier, driven mainly by a sharp increase in revenue from the transfer of intellectual property and other, including $29.4 million recognized from shares received under an amended Nicoya license for RAYALDEE in Greater China. Operating loss improved to $7.0 million from $60.0 million, and net loss narrowed to $8.4 million, or $0.01 per share, versus $148.4 million, or $0.19 per share, in 2025.
Pharmaceutical revenue rose to $89.0 million from $55.7 million, with RAYALDEE sales increasing to $8.1 million and NGENLA profit share reaching $6.4 million. Diagnostics services revenue declined to $74.5 million from $101.1 million, reflecting the 2025 oncology divestiture, but segment operations produced $4.8 million of income, aided by an $18.1 million Labcorp earnout. Cash, cash equivalents, marketable securities and restricted cash totaled $314.4 million, and OPKO had repurchased approximately $105.3 million of common stock under its buyback program, with $94.7 million remaining authorized. The company also highlighted progress across multiple ModeX and OPK clinical programs and issued 2026 revenue guidance of $560–$585 million.
OPKO Health (NASDAQ: OPK) will report its second-quarter 2026 operating and financial results on Monday, July 27, 2026. Senior management will host a conference call and webcast at 4:30 p.m. ET, with live access via pre-registration or dial-in and replays available through early August 2026.
OPKO Health (NASDAQ:OPK), through OPKO Biologics, presented preclinical data for OPK8801001, a novel long-acting hGH receptor antagonist for acromegaly, at ENDO 2026.
In vivo studies showed robust, dose-dependent, sustained IGF-1 suppression, and in vitro data indicated about 20-fold stronger receptor antagonism than Pegvisomant, suggesting a differentiated, once-weekly treatment candidate that may ease daily therapy burden and supports OPKO’s long-acting protein platform.
OPKO Health (NASDAQ:OPK) announced that subsidiary ModeX Therapeutics will present preclinical data on its MDX3001 candidate at the ASGCT 2026 Annual Meeting. Studies show in vivo CAR-T cell generation and deep systemic B-cell depletion in animal models using a CD3xCD28 antibody-conjugated LNP/mRNA platform.
OPKO Health (NASDAQ: OPK) amended its EirGen agreement with Nicoya Therapeutics to receive a 15% equity stake in Nicoya in exchange for a revised tiered royalty and transfer-price schedule, with the Series A-2 preferred share issuance closing in two tranches. The amendment expands RAYALDEE®'s Greater China field and preserves up to $115 million in milestone payments; RAYALDEE is approved in Macau and companies expect regulatory approvals in China and related territories in 2027.
BioReference (NASDAQ:OPK) launched BioReference Direct, a consumer-facing digital platform giving individuals direct online access to a menu of laboratory tests, backed by BioReference’s clinical labs and patient service centers.
The platform includes wellness panels, gender-specific tests and Abbott’s prescription-only simpli-COLLECT™ at‑home STI test with telehealth review and HIPAA-secure results delivery.
OPKO Health (NASDAQ: OPK) reported Q1 2026 results and business highlights on April 28, 2026. Consolidated revenue was $124.2 million and net loss was $54.8 million ($0.07/share). Cash and equivalents were $341.9 million as of March 31, 2026. Key pipeline updates include Phase 1 starts for MDX2301 (COVID-19 tetravalent bispecific) and MDX2003 (tetraspecific T-cell engager), ModeX in vivo CAR-T progress, and an expanded collaboration with Entera Bio targeting an IND filing in late 2026 for an oral long-acting PTH tablet. The company repurchased approximately $92.0 million of common stock since July 2025 with ~$108.0 million remaining authorized. Management provided Q2 and full-year 2026 guidance ranges.